Terrence F. Blaschke, MD,is Senior Program Officer, Clinical Pharmacology, Global Health Discovery & Translational Sciences, at the Bill and Melinda Gates Foundation in Seattle. He is also Professor of Medicine and of Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor of Biopharmaceutical Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. Dr. Blaschke received his MD from Columbia University and his residency training at UCLA. Following two years at the NIH and fellowship training in Clinical Pharmacology at UCSF he joined the Stanford faculty in 1974. Dr. Blaschke is a past president of the American Society for Clinical Pharmacology and Therapeutics and the recipient of the Oscar B. Hunter award from ASCPT. He is past chair of the Generic Drugs Advisory Committee of the US FDA, a past member of the Nonprescription Drugs Advisory Committee and past chair of the Drug Utilization Review Panel of USP. He served on the Board of Directors of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals and is now a director of DURECT Corporation, a specialty pharmaceutical company. He was a member of the AIDS Clinical Trials Group at its inception, and served as chair of the Pharmacology Committee and a member of the Executive Committee. His research has been primarily clinical, with a focus on HIV infection and an emphasis on modeling exposure-response relationships and adherence. His involvement in clinical trials, with the FDA and with the pharmaceutical industry has resulted in a strong interest in new approaches to improve the efficiency of drug development. Dr. Blaschke has over 180 original publications and is an Associate Editor of the Annual Review of Pharmacology and Toxicology, and an Executive Editor of the British Journal of Clinical Pharmacology.